share_log

复旦张江(01349.HK):注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤I期临床试验完成首例受试者入组

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced completion of enrollment of the first participant in Phase I clinical trial of injectable FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.

Gelonghui Finance ·  Jul 24 05:08

On July 24th, GLH - Fudan Zhangjiang (01349.HK) announced that the Phase I clinical trial of the injection FZ-AD005 antibody conjugate (anti-DLL3 antibody conjugate BB05) developed by the company for the treatment of advanced solid tumors has recently completed the enrollment of the first subject.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment